8 Results for "

overweight

" in MedChemExpress (MCE) Product Catalog:
Products (8)

8 Results for "overweight" in MCE Product Catalog:

1
Beinaglutide
Beinaglutide
0 Images
1 Cited Publications
Cat. No.: HY-P3463
CAS No.: 123475-27-4
Synonyms: GLP-1 (human)
Target:  

GCGR

Research Areas:  

Metabolic Disease Inflammation/Immunology

Beinaglutide is a human GLP-1 polypeptide that shares almost 100% homology with human GLP-1 (7–36). Beinaglutide displays does-dependent effects in glycemic control, inhibiting food intake and gastric empty and promoting weight loss. Beinaglutide has the potential for the research of overweight/obesity and nonalcoholic steatohepatitis (NASH) .
loading...
    loading...
View All Sizes
Zenagamtide sodium
Zenagamtide sodium
0 Images
Cat. No.: HY-P11274A
Synonyms: Amycretin sodium; NN 9487 sodium
Target:  

Amylin Receptor Insulin Receptor GCGR

Research Areas:  

Metabolic Disease

Zenagamtide (Amycretin; NN 9487) sodium is an orally active, blood-brain barrier permeable triple agonist that targets GLP-1, amylin (Amylin Receptor) and calcitonin receptor (Calcitonin Receptor). Zenagamtide sodium is a single peptide consisting of 68 amino acids that can target brain regions regulating food intake, significantly suppress appetite and reduce energy intake. Therefore, Zenagamtide sodium improves body weight, waist circumference, glycated hemoglobin and lipid profile, and also alleviates the histological features of metabolic dysfunction-associated steatotic liver disease (MASLD) and enhances insulin sensitivity. Zenagamtide sodium may cause transient increases in heart rate and fluctuations in serum calcium levels, but it is an important compound for the study of overweight, obesity, insulin resistance and related metabolic diseases .
loading...
    loading...
View All Sizes
Zenagamtide
Zenagamtide
0 Images
Cat. No.: HY-P11274
CAS No.: 3005889-81-3
Synonyms: Amycretin; NN 9487
Target:  

Amylin Receptor GCGR Insulin Receptor

Research Areas:  

Metabolic Disease

Zenagamtide (Amycretin; NN 9487) is an orally active, blood-brain barrier permeable triple agonist that targets GLP-1, amylin (Amylin Receptor) and calcitonin receptor (Calcitonin Receptor). Zenagamtide is a single peptide consisting of 68 amino acids that can target brain regions regulating food intake, significantly suppress appetite and reduce energy intake. Therefore, Zenagamtide improves body weight, waist circumference, glycated hemoglobin and lipid profile, and also alleviates the histological features of metabolic dysfunction-associated steatotic liver disease (MASLD) and enhances insulin sensitivity. Zenagamtide may cause transient increases in heart rate and fluctuations in serum calcium levels, but it is an important compound for the study of overweight, obesity, insulin resistance and related metabolic diseases .
loading...
    loading...
View All Sizes
NSC 90469
NSC 90469
0 Images
Cat. No.: HY-114557
CAS No.: 1041-01-6
Purity:  99.38%
Synonyms: 3,5-Diiodo-L-thyronine
Category:  

Monophenols Ketones, Aldehydes, Acids Metabolic Disease Phenols Endogenous metabolite Disease Research Fields

Target:  

JNK NF-κB Sirtuin PGC-1α COX TGF-β Receptor Collagen

NSC 90469 (3,5-Diiodo-L-thyronine) is an orally active thyroid hormone derivative. NSC 90469 inhibits JNK phosphorylation and NF-κB acetylation, blocks SIRT1 protein expression, induces elevated PGC-1α levels, and stimulates COX activity. NSC 90469 enhances UCP1-mediated thermogenesis, increases hepatic Dio1 activity, inhibits TSH levels and hypothalamic-pituitary-thyroid axis function, enhances lipid metabolism, and regulates energy metabolism via the mitochondrial pathway. NSC 90469 prevents blood glucose reduction, reduces urinary albumin excretion, inhibits renal matrix expansion, decreases TGF-β1 expression, and reduces renal fibronectin and type Ⅳ collagen deposition. NSC 90469 also increases energy expenditure and prevents diet-induced overweight. NSC 90469 can be used in studies related to diabetic nephropathy, hypothyroidism, non-alcoholic fatty liver disease, and diet-induced obesity .
loading...
    loading...
View All Sizes
Aclimostat
Aclimostat
0 Images
Cat. No.: HY-114196
CAS No.: 2082752-83-6
Purity:  ≥98.0%
Synonyms: ZGN-1061
Target:  

MetAP

Research Areas:  

Metabolic Disease Cancer

Aclimostat (ZGN-1061) is a methionine aminopeptidase 2 (MetAP2) inhibitor. Aclimostat exhibits anti-obesity, anti-diabetic and ovarian cancer-related activities, and does not readily distribute to the central nervous system. Aclimostat acts on the active site of MetAP2 via irreversible covalent binding, and blocks enzyme activity through interactions with His231 and His339. Aclimostat regulates gene expression, reduces fat mass, plasma glucose, insulin levels, LDL-C, hs-CRP and leptin levels, while increasing adiponectin levels. Aclimostat can be used in research related to type 2 diabetes, overweight, obesity and ovarian cancer .
loading...
    loading...
View All Sizes
NSC 90469 (Standard)
NSC 90469 (Standard)
0 Images
Cat. No.: HY-114557R
CAS No.: 1041-01-6
Synonyms: 3,5-Diiodo-L-thyronine (Standard)
Category:  

Monophenols Ketones, Aldehydes, Acids Phenols Endogenous metabolite

Target:  

Reference Standards COX Sirtuin PGC-1α NF-κB TGF-β Receptor JNK Collagen

NSC 90469 (Standard) is the analytical standard of NSC 90469. This product is intended for research and analytical applications. NSC 90469 (3,5-Diiodo-L-thyronine) is an orally active thyroid hormone derivative. NSC 90469 inhibits JNK phosphorylation and NF-κB acetylation, blocks SIRT1 protein expression, induces elevated PGC-1α levels, and stimulates COX activity. NSC 90469 enhances UCP1-mediated thermogenesis, increases hepatic Dio1 activity, inhibits TSH levels and hypothalamic-pituitary-thyroid axis function, enhances lipid metabolism, and regulates energy metabolism via the mitochondrial pathway. NSC 90469 prevents blood glucose reduction, reduces urinary albumin excretion, inhibits renal matrix expansion, decreases TGF-β1 expression, and reduces renal fibronectin and type Ⅳ collagen deposition. NSC 90469 also increases energy expenditure and prevents diet-induced overweight. NSC 90469 can be used in studies related to diabetic nephropathy, hypothyroidism, non-alcoholic fatty liver disease, and diet-induced obesity .
loading...
    loading...
View All Sizes
9,12-Hexadecadienoylcarnitine
9,12-Hexadecadienoylcarnitine
0 Images
Cat. No.: HY-N19253
CAS No.: 1911579-97-9
Category:  

Lipids Endogenous metabolite

Target:  

Endogenous Metabolite

9,12-Hexadecadienoylcarnitine is an acylcarnitine. The level of 9,12-Hexadecadienoylcarnitine increases during mild weight loss induced by a 12-week low-calorie diet. The serum level of 9,12-Hexadecadienoylcarnitine is upregulated in models of reduced intrinsic capacity. 9,12-Hexadecadienoylcarnitine can be used in studies related to overweight and reduced intrinsic capacity .
loading...
    loading...
View All Sizes
Elecoglipron
Elecoglipron
0 Images
Cat. No.: HY-159055
CAS No.: 3011682-49-5
Synonyms: ECC5004; AZD5004
Target:  

GLP Receptor

Research Areas:  

Metabolic Disease

Elecoglipron (AZD5004) is an orally active small-molecule GLP-1R agonist. Its IC50 against human GLP-1R is 2.4 nM. It activates the cAMP signaling pathway in HEK293 cells overexpressing human GLP-1R with a potency of 2.1 nM, and enhances glucose-stimulated insulin secretion in EndoC-βH5 cells with an EC50 of 5.9 nM, with no detectable β-arrestin-2 recruitment or GLP-1R internalization. Elecoglipron can be used in research related to obesity, overweight and type 2 diabetes .
loading...
    loading...
View All Sizes
Assay Types